ASCO1

Positive data for the use of radioligand therapy in first-line neuroendocrine cancers

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant

PD-1–refractory advanced melanoma: how do we get to the finish line?

Immunotherapy significantly increases the number of patients free from bowel cancer

ASCO /
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer

ASCO /
Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

ASCO /
Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life

ASCO /
Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer

ASCO /
Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer

ASCO /
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment

ASCO /
Comment: The success of immunotherapy means we have to change our mindset as we treat patients

ASCO /
MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer

ASCO /
POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer

ASCO 2019 /
Breast cancer highlights from ASCO 2019

ASCO 2019 /
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC

TATTON: Updated results for patients with EGFR-mutant NSCLC

Cancer preventive vaccine showed promising results in preclinical model of Lynch syndrome

HER2-targeted CAR T-cell therapy safe and showing promising antitumour activity in patients with advanced sarcoma

Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients with advanced solid tumours

KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lung cancer

ASCO 2019 /
Expanded clinical trial inclusion criteria would double the percentage of patients eligible to enrol in clinical trials

ASCO 2019 /
No difference in survival between laparoscopic surgery and open surgery in colorectal cancer patients with liver metastases

ASCO 2019 /
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC

ASCO 2019 /
EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer

ASCO 2019 /
Ado-trastuzumab emansine in patients with HER2 amplified salivary gland cancers: Results from a phase II basket trial